Updated: February 20, 2021 12:55:55 pm
PATANJALI’S DIVYA Coronil has received certification from AYUSH Ministry as per WHO norms as a drug that can be used as “supporting measure in Covid-19” and as an immuno-booster. “Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme,” Patanjali said in a statement.
Making the announcement at a press meet, Yoga guru and Patanjali group founder Ramdev also released a booklet with nine peer-reviewed papers certifying Coronil’s efficacy. The press meet was also attended by Health Minister Harsh Vardhan and Transport and Highways Minister Nitin Gadkari.
In June last year, Patanjali launched Coronil tablets developed at Haridwar-based Divya Prakashan Patanjali Research Institute, claiming that it cures Covid-19 in seven days. The AYUSH Ministry then banned Patanjali from selling it as a “cure” and sought information on its trials. The Rajasthan government also served a notice to NIMS Hospital in Jaipur where its trials were being conducted on Covid patients, stating that it could not be used as a medicine until cleared by AYUSH Ministry.
According to CoPP certification, the drug can be exported to 158 countries, and allows the WHO to inspect the manufacturer at “suitable intervals”.
Ramdev said, “We are using modern medicinal and scientific protocols and evidence-based research to prove the validity of Ayurvedic practices.” Harsh Vardhan, also chairperson of WHO’s executive board, said, “During British colonial times, Ayurveda should have been recognised, its knowledge publicised… Unfortunately, we had to wait till Independence to do that. Ayurveda has been accepted and established in many countries such as Australia, New Zealand, Cuba, Bangladesh, China and Sri Lanka. The 30,000-crore industry for Ayurvedic products which grew at 15-20% per year is growing at 50-90% after Covid.”
📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines